Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2024
0mins
Should l Buy PAVM?
Source: PRnewswire
Company Presentation Announcement: Lucid Diagnostics Inc. will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21, 2024, with live webcasts available for viewing.
Focus on Cancer Prevention: Lucid Diagnostics specializes in cancer prevention through its EsoGuard® Esophageal DNA Test and EsoCheck® device, targeting patients with gastroesophageal reflux disease (GERD) to detect esophageal precancer early.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAVM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAVM
Wall Street analysts forecast PAVM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.800
Low
17.00
Averages
17.00
High
17.00
Current: 9.800
Low
17.00
Averages
17.00
High
17.00
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PAVmed Reports Q4 2025 Financial Results with Key Metrics
- Financial Performance: PAVmed reported a Q4 2025 non-GAAP EPS of -$1.05, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, PAVmed had cash and cash equivalents of $1.5 million, an increase from $1.2 million in the same period of 2024, suggesting improved cash management despite ongoing operational challenges.
- Operating Expenses: The company's operating expenses for Q4 2025 were approximately $6.9 million, which included $0.3 million in stock-based compensation, highlighting the financial pressures associated with ongoing operations and employee incentives.
- Reverse Stock Split: PAVmed announced a 1-for-30 reverse stock split, a strategic move aimed at increasing the share price to attract more investor interest, although it may impact liquidity in the short term.
See More
PAVmed Reports Q4 2025 Earnings with Key Metrics
- Revenue and Test Volume Growth: PAVmed reported $1.5 million in revenue for Q4 2025, with EsoGuard test volume reaching 3,664, a 29% increase from Q3, indicating rising market demand in the medical testing sector, although overall financial health remains challenged.
- Net Loss and Operating Expenses: The company faced a GAAP net loss of $2.8 million in Q4, with a non-GAAP loss of $942,000, while operating expenses have remained nearly flat since Lucid's deconsolidation in 2024, reflecting efforts to control costs amidst ongoing financial pressures.
- Strategic Restructuring and Financing: PAVmed successfully completed a restructuring recapitalization, eliminating toxic convertible securities and achieving a clean capital structure, which lays a foundation for future business development and enhances financial stability.
- New Technologies and Market Expansion: PAVmed is relaunching its MedTech portfolio with a focus on innovative technologies, including an endoscopic imaging technology licensed from Duke University, which, despite being in early stages, holds potential for future growth through commercialization efforts.
See More
PAVmed Restructures Capital and Relaunches Product Line
- Capital Structure Optimization: Over the past two years, PAVmed has undertaken a series of systematic actions to repair its legacy capital structure, successfully strengthening its balance sheet, which is expected to lay a solid foundation for the company's future high growth.
- Strategic Partnership Progress: Veris Health is advancing its strategic partnership with Ohio State University into the commercial phase, while its implantable physiological monitor is progressing toward FDA submission, indicating ongoing innovation in personalized cancer care.
- Medical Device Portfolio Relaunch: PAVmed has relaunched its medical device product portfolio under new leadership and completed the licensing of its endoscopic esophageal imaging technology from Duke University, further enriching the company's growth engines.
- EsoGuard Coverage Expansion: Lucid Diagnostics is nearing transformative Medicare coverage, continuously expanding the accessibility and clinical evidence base of the EsoGuard healthcare system, which is expected to significantly enhance its market competitiveness.
See More
Lucid Diagnostics Reports Q4 Highlights and Revenue Growth
- Revenue Growth: Lucid Diagnostics reported $1.5 million in revenue for Q4 2025, a 25.5% increase from $1.197 million in 2024, indicating sustained market demand in cancer prevention.
- Contract Expansion: The company secured a contract with the U.S. Department of Veterans Affairs, enhancing EsoGuard's accessibility, which not only increases market penetration but also lays a foundation for future revenue growth.
- Strengthened Clinical Evidence: By presenting the largest reported real-world experience in esophageal precancer detection, Lucid has bolstered the clinical evidence for EsoGuard, which will help enhance trust among physicians and patients, thereby driving broader adoption of the product.
- Future Outlook: Lucid plans to deepen its relationship with the VA, expand adoption across health systems, and secure Medicare coverage in 2026, with these initiatives expected to further drive revenue growth.
See More
PAVmed to Announce Q4 Earnings on March 30
- Earnings Announcement: PAVmed is set to release its Q4 2023 earnings on March 30 at 8:30 AM ET, with a consensus EPS estimate of -$4.50, reflecting a staggering 7400% year-over-year decline, indicating significant profitability challenges ahead.
- Historical Performance: Over the past two years, PAVmed has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, although the current expectations suggest a notable downturn, highlighting the company's volatility in profitability.
- Subsidiary Success: PAVmed's subsidiary, Lucid Diagnostics, saw a spike in stock price due to a contract with the Veterans Affairs, which could provide a new revenue stream and enhance the company's competitive position in the market.
- Reverse Stock Split Impact: PAVmed recently announced a 1-for-30 reverse stock split aimed at boosting its stock price to meet listing requirements, which may affect investor confidence and market performance.
See More
PAVmed to Host Business Update Conference Call
- Conference Details: PAVmed will host a business update conference call on March 30, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will discuss the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results Discussion: CFO Dennis McGrath will present the fourth quarter 2025 financial results during the call, expected to reveal the company's performance in the medical device and digital health sectors, assisting investors in assessing market positioning.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, ensuring global investors can access real-time updates, thereby enhancing transparency and communication efficiency.
- Replay Service: A replay of the call will be available for 30 days post-conference on the investor relations section of the website, allowing investors who missed the live event to review the content, further improving information accessibility and interaction with stakeholders.
See More
PAVmed Reports Q4 2025 Financial Results with Key Metrics
- Financial Performance: PAVmed reported a Q4 2025 non-GAAP EPS of -$1.05, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, PAVmed had cash and cash equivalents of $1.5 million, an increase from $1.2 million in the same period of 2024, suggesting improved cash management despite ongoing operational challenges.
- Operating Expenses: The company's operating expenses for Q4 2025 were approximately $6.9 million, which included $0.3 million in stock-based compensation, highlighting the financial pressures associated with ongoing operations and employee incentives.
- Reverse Stock Split: PAVmed announced a 1-for-30 reverse stock split, a strategic move aimed at increasing the share price to attract more investor interest, although it may impact liquidity in the short term.
See More
PAVmed Reports Q4 2025 Earnings with Key Metrics
- Revenue and Test Volume Growth: PAVmed reported $1.5 million in revenue for Q4 2025, with EsoGuard test volume reaching 3,664, a 29% increase from Q3, indicating rising market demand in the medical testing sector, although overall financial health remains challenged.
- Net Loss and Operating Expenses: The company faced a GAAP net loss of $2.8 million in Q4, with a non-GAAP loss of $942,000, while operating expenses have remained nearly flat since Lucid's deconsolidation in 2024, reflecting efforts to control costs amidst ongoing financial pressures.
- Strategic Restructuring and Financing: PAVmed successfully completed a restructuring recapitalization, eliminating toxic convertible securities and achieving a clean capital structure, which lays a foundation for future business development and enhances financial stability.
- New Technologies and Market Expansion: PAVmed is relaunching its MedTech portfolio with a focus on innovative technologies, including an endoscopic imaging technology licensed from Duke University, which, despite being in early stages, holds potential for future growth through commercialization efforts.
See More
PAVmed Restructures Capital and Relaunches Product Line
- Capital Structure Optimization: Over the past two years, PAVmed has undertaken a series of systematic actions to repair its legacy capital structure, successfully strengthening its balance sheet, which is expected to lay a solid foundation for the company's future high growth.
- Strategic Partnership Progress: Veris Health is advancing its strategic partnership with Ohio State University into the commercial phase, while its implantable physiological monitor is progressing toward FDA submission, indicating ongoing innovation in personalized cancer care.
- Medical Device Portfolio Relaunch: PAVmed has relaunched its medical device product portfolio under new leadership and completed the licensing of its endoscopic esophageal imaging technology from Duke University, further enriching the company's growth engines.
- EsoGuard Coverage Expansion: Lucid Diagnostics is nearing transformative Medicare coverage, continuously expanding the accessibility and clinical evidence base of the EsoGuard healthcare system, which is expected to significantly enhance its market competitiveness.
See More
Lucid Diagnostics Reports Q4 Highlights and Revenue Growth
- Revenue Growth: Lucid Diagnostics reported $1.5 million in revenue for Q4 2025, a 25.5% increase from $1.197 million in 2024, indicating sustained market demand in cancer prevention.
- Contract Expansion: The company secured a contract with the U.S. Department of Veterans Affairs, enhancing EsoGuard's accessibility, which not only increases market penetration but also lays a foundation for future revenue growth.
- Strengthened Clinical Evidence: By presenting the largest reported real-world experience in esophageal precancer detection, Lucid has bolstered the clinical evidence for EsoGuard, which will help enhance trust among physicians and patients, thereby driving broader adoption of the product.
- Future Outlook: Lucid plans to deepen its relationship with the VA, expand adoption across health systems, and secure Medicare coverage in 2026, with these initiatives expected to further drive revenue growth.
See More
PAVmed to Announce Q4 Earnings on March 30
- Earnings Announcement: PAVmed is set to release its Q4 2023 earnings on March 30 at 8:30 AM ET, with a consensus EPS estimate of -$4.50, reflecting a staggering 7400% year-over-year decline, indicating significant profitability challenges ahead.
- Historical Performance: Over the past two years, PAVmed has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, although the current expectations suggest a notable downturn, highlighting the company's volatility in profitability.
- Subsidiary Success: PAVmed's subsidiary, Lucid Diagnostics, saw a spike in stock price due to a contract with the Veterans Affairs, which could provide a new revenue stream and enhance the company's competitive position in the market.
- Reverse Stock Split Impact: PAVmed recently announced a 1-for-30 reverse stock split aimed at boosting its stock price to meet listing requirements, which may affect investor confidence and market performance.
See More
PAVmed to Host Business Update Conference Call
- Conference Details: PAVmed will host a business update conference call on March 30, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will discuss the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results Discussion: CFO Dennis McGrath will present the fourth quarter 2025 financial results during the call, expected to reveal the company's performance in the medical device and digital health sectors, assisting investors in assessing market positioning.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, ensuring global investors can access real-time updates, thereby enhancing transparency and communication efficiency.
- Replay Service: A replay of the call will be available for 30 days post-conference on the investor relations section of the website, allowing investors who missed the live event to review the content, further improving information accessibility and interaction with stakeholders.
See More
